Diagnosis of multiple myeloma (MM) is based on diagnostic criteria which include clonal plasma cell (PC) percentage, quantity of monoclonal protein and presence of CRAB symptoms (hypercalcemia, renal insufficiency, anemia, bone lesion).\textsuperscript{1,2} According to the previously adopted world health organization (WHO) 2008 criteria, the presence of clonal plasma cells is considered as key evidence of clonal plasma cell proliferation, irrespective of the percentage of PC and CRAB symptom counts. However, some patients with related organ or tissue impairment symptoms show <10% plasma cells in bone marrow (BM) aspiration. Empirically, there are three indwelling problems with the original criteria utilizing the percentage of plasma cells. Firstly, BM aspiration (BMA) diluted by peripheral blood results in variable plasma cell percentages. At present, no consensus has been made on the ideal diagnostic amount of BM aspirate. Usually, the amount varies from 0.3 to 3 ml depending on the practitioner. Secondly, uneven distribution of plasma cells or patchy infiltration can result in markedly discrepant counts of plasma cells between BMA and biopsy. Thirdly, counting plasma cell % using BM biopsy (BMB) lacks objectiveness, thus making it inapplicable for routine diagnosis.

Recently, international myeloma working group (IMWG) presented revised criteria on BM cell requirement. In the revised criteria, the percentage of BM plasma cells was emphasized for the diagnosis and discrimination between monoclonal gammopathy of undetermined significance (MGUS) and MM. The most important criterion in diagnosing MM is the presence of clonal plasma cells >10%, whilst a major change from previous criteria is that CRAB features no longer serve as evidence of clonal PC proliferation if bone marrow plasmacytosis is less than 10% and there is no biopsy-proven plasmacytoma.\textsuperscript{3–5} In addition, to exclude sampling error or patchy bone marrow involvement, IMWG recommend plasma cell % either by aspiration or biopsy, with the higher value being used in cases of discrepancy. This is a modification to the previous version which indicated BMB PC% as non-mandatory.\textsuperscript{6} The percentage of BM PC is also mentioned as a biomarker of malignancy, with a percentage greater than 60% regarded as a myeloma defining event.\textsuperscript{7,8} Overall, the exact measurement of BM PC is becoming more crucial for the diagnosis of MM, and the introduction of CD138 immunohistochemical stain using BMB has made it possible for more accurate PC counts.\textsuperscript{9,10,11} We designed this study to evaluate PC% of BMB in patients with low BMA PC (<10%) and tracked the conversion rate from BMA PC (<10%) to BMB PC (≥10%).

A total of 389 patients newly diagnosed with MM were enrolled and 67 patients of BMA PC count below 10% were selected. Among 73 cases (67 patients with aspiration PC <10% and 6 patients with unknown PC percentage), 58 were available for analysis of BMB (Figure 1a). For image analysis, CD138 staining using ultraView Universal DAB Detection Kit on BM section was conducted and Image J software, provided by National Institutes of Health (https://imagej.nih.gov/ij/) was utilized. After obtaining the full slide image, the representative image (area cover per spot, 0.96 mm\textsuperscript{2}) was selected, and according to the guidelines, the thresholds of hue, saturation, and brightness were adjusted to detect the cytoplasm of plasma cells and nucleus of the other cells (Figure 1b). The total area of plasma cells and the other cells were evaluated separately, and divided by the average size of each cell to count the number of corresponding cells.

From the aforementioned 58 cases, 55 patients demonstrated a BMB PC count of ≥10%, and only 3 patients showed a BM PC count below 10% (Figure 1a). Mean percentage of PC in BMB was 52.9%, with a standard deviation of 30.7. Interestingly, we observed a bimodal peak in the 20-30% PC percentage group and packed marrow (90-100%) group (Figure 1c). Upon review of BM reports for specimen adequacy, the aspiration quality of only 39.7% of the patients was adequate, and the remaining 60.3% of patients either had mild to severe dilution, or few visible particles. Most of the patients with diluted BMA were found to have an increased PC% on BMB. Patchy infiltration or site variation of plasma cell infiltration was observed in seven patients (Figure 1d).

Clinical features assessed at diagnosis including age, sex, anthropometric laboratory values, and molecular parameters were evaluated by a non-parametric method. The patients were divided into two groups on the basis of BMA PC% (≥10% or <10%) and the patients with BMA PC <10% were further subdivided into two groups on the basis of BMB PC% (≥10% or <10%). Creatinine and total protein were statistically significant to be higher in BMA PC ≥10% patients than those of BMA PC <10% patients by Mann-Whitney test, whilst albumin was significantly lower in BMA PC >10% patients than that of BMA PC <10% patients (Table 1a).

Additionally, the patients who showed BMA PC% below 10% (a total of 58 patients) were enrolled for investigating the correlation of related clinical parameters. There were moderate positive correlations of β2-microglobulin, BUN, and free light chain (FLC) ratio with BMB PC%, and calcium showed mild correlation with BMB PC%. Correlations of aberrant FISH results among PC% were statistically significant in RB1 deletion, IgH rearrangement, and 1q gain (Table 1b). These patients were also evaluated for prognostic importance. Overall survival (OS) by Kaplan-Meier estimation showed adverse survival rates in high BMB PC% compared to low BMB PC% group (p = 0.010). The cutoff value was set as the mean of total BMB PC%, and median OS for high and low BMB PC% group was 93.2 and 67.9 months, respectively (Supplementary Figure 1A). Conversely, BMA PC% showed no significant difference in survival times when analyzed with the same parameters (Supplementary Figure 1B). Univariate Cox analysis showed increased creatinine, BMB PC%, and FLC ratio over 100 to be significantly associated with adverse OS. Among the FISH results, percentage of RB deletion and IgH rearrangement were represented to significant factors (Table 1c).

In the present study, we analyzed the percentage of BMB PC in MM patients with low BMA PC (<10%). Objective measurement of PC% in BM biopsy was performed with BM section stained with CD138, using an image analyzer. The conversion rate of BMA PC <10% patients to >10% in BMB was 75.0% (55/73 patients). Most
patients with less than 10% of BMA PC% had diluted BM aspiration and showed diffuse infiltration of plasma cells in BMB, whilst several other patients showed patchy or site varied infiltration.

According to a previous report, about 4% of patients diagnosed with MM showed low plasma cell counts (< 10%). Also, there has been many studies reporting the discrepancy of BMA and BMB. It would currently be difficult to diagnosis myeloma with only a BMA specimen, thus BMB PC% is expected to help calculate the exact PC amount in each patient. The recently revised IMWG MM criteria also indicate that the higher PC count of either aspiration or biopsy should be considered in cases of discrepancy between specimens. In addition, we found that BMB PC% moderately correlated with corresponding end organ disorders.

**Figure 1.** (a) Flow chart for patient selection and study design. In a total of 389 newly diagnosed MM patients, 81.2% (316/389) patients had a PC > 10%, and the remaining 18.8% (73/389) of patients had either a PC < 10% or were unavailable for BMA PC estimation. Of these 73 patients, 55 patients showed PC > 10% after estimation by image analysis in bone marrow biopsy. (b) Screenshot of plasma cell counting via ImageJ software program. Cytoplasm of plasma cells stained with CD138 is represented in red. Adjustment of the ‘Hue’, ‘Saturation’, and ‘Brightness’ thresholds using ImageJ. (c) Distribution of BMB PC percentage among patients with BMA PC less than 10%. When the PC percentage was divided by an interval of 10%, distribution of BMB PC % showed a bimodal peak of 20-30% and 90-100%. (d) Classification of patients by bone marrow aspiration quality. Only 39.7% of patients had adequate aspiration quality; the remaining 60.3% of patients had mild to severe dilution. Patchy infiltration/site variation of plasma cell infiltration was shown in 7 patients. MM, multiple myeloma; BM, bone marrow; PC, plasma cell; BMA PC, bone marrow aspiration plasma cell; BMB PC, bone marrow biopsy plasma cell.
Despite previous attempts to count accurate PC% via multicolor image analysis (imageJ software) of CD138+ cells in BM biopsy, the lack of objectiveness for counting BMB PC% by applying alone harbors the risk of not re-revised IMWG guideline. Since plasma cell counts on BMA or BMB and prognostication, and the PC count is re-emphasized in the recent revision. In MM, quantitation of plasma cells is crucial for diagnosis and prognostication, and the PC count is re-emphasized in the revised IMWG guideline. Since plasma cell counts on BMA or BMB alone harbors the risk of not reflecting the true plasma cell burden, we suggest that the higher value of the PC% among BMB or BMA should be used. In addition, we recommend the potential use of image analysis as a routine tool for objective PC counting in BMB.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-2014R1 A2A1A10052286).

N Lee1, SY Moon1, J-h Lee1, H-K Park2, S-Y Kong3, S-M Bang4, JH Lee5, S-S Yoon6 and DS Lee1
1Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea;
REFERENCES

1 Swerdlow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press: France, 2008.

2 Kyle R, Child J, Anderson K, Barlogie B, Bataille R, Bensinger W et al. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

3 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–e548.

4 Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP et al. Monoclonal gammapathy of renal significance: when MGUS is no longer under-terminate or insignificant. Blood 2012; 120: 4292–4295.

5 Sethi S, Rajkumar SV. Monoclonal gammapathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013; 88: 1284–1293.

6 Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001; 68: 269–275.

7 Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365: 474–475.

8 Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellas N, Eleftherakis-Papaiakovou E et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013; 27: 947–953.

9 Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquín M et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013; 54: 2215–2218.

10 Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol 2007; 38: 1779–1787.

11 Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.

12 Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

13 Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 2010; 63: 213–216.

14 Štifter S, Babarović E, Valković T, Seili-Beka C, Načinović A et al. Combined evaluation of bone marrow aspirate and biopsy is superior in the diagnosis of multiple myeloma. Diagn Pathol 2010; 5: 30.

15 Paiva B, Vidriales MB, Perez JJ, Mateo G, Montalban MA, Mateos MV et al. Multi-parameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009; 94: 1599–1602.